BDBM2391 US8507533, 147
SMILES: OC(=O)CCNC(=O)c1ccc(cc1)[C@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1
InChI Key: InChIKey=BUHOCUGQWONNJV-XMMPIXPASA-N
Data: 1 KI
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pro-glucagon (Homo sapiens (Human)) | BDBM2391 (US8507533, 147) | Reactome pathway KEGG UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | 26.7 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pfizer Inc. US Patent | Assay Description The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors. | US Patent US8507533 (2013) BindingDB Entry DOI: 10.7270/Q23R0RGH | |||||||||||
More data for this Ligand-Target Pair |